New diabetes clinical trial: Observational Study of ASCVD Risks of Type 2 Diabetes in East China

Published on: April 30, 2021 at 09:30PM
Conditions:   Type 2 Diabetes Mellitus;   Arteriosclerotic Cardiovascular Disease;   Liraglutide
Intervention:  
Sponsors:   Zhejiang Provincial People's Hospital;   Zhejiang Provence Preventive Medicine Association;   Ningbo Medical Center Lihuili Hospital;   Affiliated Cixi Hospital of Wenzhou Medical University;   Putuo People's Hospital;   The Second People's Hospital of Yuhuan;   Wenling People's Hospital;   ShuGuang Hospital;   The First People's Hospital of Jiaxing;   Nanxun People's Hospital;   First People's Hospital Affiliated to Huzhou University;   Lishui Hospital of TCM;   Hangzhou hospital of Chinese Traditional Medicine;   Zhejiang Greentown Cardiovascular Hospital;   Red Cross Hospital of Hangzhou;   The Second School of Medicine，WMU;   The First People's Hospital of Xiaoshan;   Zhejiang Xiaoshan hospital;   Yiwu Central Hospital;   Quzhou Hospital;   Jinhua Hospital of TCM;   Shaoxing Central Hospital;   Shaoxinig Second Hospital;   Huamei hospital, University of Chinese Academy of Sciences
Not yet recruiting
https://ift.tt/3vtmkFq